Pre-clinical studies with mRNA for correction of variants in CCDC40 are progressing in Europe, and Phase 1 trials using inhaled mRNA therapy to correct DNAI1 defects are currently being administered to people with PCD and healthy controls [194]. Here, DNAI1 is linked to primary ciliary dyskinesia.